TAMARA CLARK: Open Payments
NPI 1598772147 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$613 in 28 payments from 8 companies in 2025. Trend: 2023 $844 · 2024 $586 · 2025 $613
Food & beverage: $528Education: $85
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 7 | $291 |
| MAYNE PHARMA COMMERCIAL LLC | 10 | $106 |
| Biogen, Inc. | 3 | $55 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| ABBVIE INC. | 2 | $44 |
| Exeltis, USA Inc. | 2 | $31 |
| Organon LLC | 1 | $25 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $15 |
Products named: Veozah, ZURZUVAE, MYFEMBREE, SLYND, NEXPLANON, QULIPTA, LO LOESTRIN FE, Mirena.
Industry payments across NE — which companies pay providers there.
